What Is the Threshold for Symptomatic Response and Remission for Major Depressive Disorder, Panic Disorder, Social Anxiety Disorder, and Generalized Anxiety Disorder?
The DOI matches its Crossref record.
Abstract
OBJECTIVE: Symptom-free remission is a goal for treatment in depression and anxiety disorders, but there is no consensus regarding the threshold for determining remission in individual disorders. We sought to determine these thresholds by comparing, in a post hoc analysis, scores on the Clinical Global Impressions scale (CGI) and disorder-specific symptom severity rating scales from all available studies of the treatment of major depressive disorder, panic disorder, generalized anxiety disorder, and social anxiety disorder with the same medication (escitalopram). We also sought to compare the standardized effect sizes of escitalopram for these 4 psychiatric disorders. DATA SOURCES AND STUDY SELECTION: Raw data from all randomized, double-blind, placebo-controlled, acute treatment studies sponsored by H. Lundbeck A/S (Copenhagen, Denmark) or Forest Laboratories, Inc. (New York, N.Y.), published through March 1, 2004, with patients treated with escitalopram for DSM-IV major depressive disorder (5 studies), panic disorder (1 study), generalized anxiety disorder (4 studies), or social anxiety disorder (2 studies) were compared with regard to the standardized effect sizes of change in CGI score and scores on rating scales that represent the "gold standard" for assessment of these disorders (the Montgomery-Asberg Depression Rating Scale, the Panic and Agoraphobia Scale, the Hamilton Rating Scale for Anxiety, and the Liebowitz Social Anxiety Scale, respectively). DATA SYNTHESIS: In all indications, treatment with escitalopram showed differences from placebo in treatment effect from 0.32 to 0.59 on the CGI-S and CGI-I and standardized effect sizes from 0.32 to 0.50 on the standard rating scales. There were no significant differences among the different disorders. Moderate to high correlations were found between scores on the CGI and the standard scales. The corresponding standard scale scores for CGI-defined "response" and "remission" were determined. CONCLUSION: Comparison of scores on the standard scales and scores on the CGI suggest that the traditional definition of response (i.e., a 50% reduction in a standard scale) may be too conservative.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“With the HAM-A, scores of 9, 15 and 24 can be interpreted as representing the lower limits of borderline, mild and moderate illness, respectively 110”
From The clinical characterization of the adult patient with an anxiety or related disorder aimed at personalization of management (2021) · cites this paper as [110]
In the citing paper
“These two groups mentioned a variety of optimal asymptomatic thresholds for the HAMD-17 ranging from ⩽2 (Zimmerman et al. 2005) to ⩽10 (Zimmerman et al. 2004b) and for the MADRS ⩽4 (Zimmerman et al. 2004a, 2004d) to ⩽11 (Bandelow et al. 2006).”
From Empirical evidence for definitions of episode, remission, recovery, relapse and recurrence in depression: a systematic review (2019) · cites this paper as Bandelow et al. 2006
In the citing paper
“Currently, there is no unequivocal definition of TRPD. Very heterogeneous criteria have been used across different studies, making interpretation of the results uncertain.”
From Management of Treatment-Resistant Panic Disorder (2017) · cites this paper as [26]
Citations
Cites
Still being checked.
Cited by
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Self-citationCarpenter, L. L., Janicak, P. G., Aaronson, S. T., Boyadjis, T., Brock, D. G., Cook, I. A., Dunner, D. L., Lanocha, K., Solvason, H. B., & Demitrack, M. A. (2012) · Depression and Anxiety · doi:10.1002/da.21969 · Cited by 367
Leichsenring, F., Salzer, S., Beutel, M. E., Herpertz, S., Hiller, W., Hoyer, J., Huesing, J., Joraschky, P., Nolting, B., Poehlmann, K., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12081125 · Cited by 298
Response and remission criteria in major depression – A validation of current practice
Riedel, M., Möller, H.-J., Obermeier, M., Schennach-Wolff, R., Bauer, M., Adli, M., Kronmüller, K., Nickel, T., Brieger, P., Laux, G., et al. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.03.006 · Cited by 288
Treatment Response, Symptom Remission, and Wellness in Obsessive-Compulsive Disorder
Farris, S. G., McLean, C. P., Van Meter, P. E., Simpson, H. B., & Foa, E. B. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m07789 · Cited by 216
Furukawa, T. A., Salanti, G., Atkinson, L. Z., Leucht, S., Ruhe, H. G., Turner, E. H., Chaimani, A., Ogawa, Y., Takeshima, N., Hayasaka, Y., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010919 · Cited by 214
“HDRS (or the corresponding threshold for longer versions of HDRS),(17) or of less or equal to 10 or 11 on the MADRS scale at week 8 (range 4–12 weeks).(18) (5) Tolerability of treatment The proportion of patients who leave the study early due to adverse events during the first 8 weeks of treatment (range 4–12 weeks).”
Backgroundde Zwart, P. L., Jeronimus, B. F., & de Jonge, P. (2019) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796018000227 · Cited by 189
Ketamine and other glutamate receptor modulators for depression in adults
Caddy, C., Amit, B. H., McCloud, T. L., Rendell, J. M., Furukawa, T. A., McShane, R., Hawton, K., & Cipriani, A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011612.pub2 · Cited by 174
Evidence‐based guidelines for interpretation of the Panic Disorder Severity Scale
Furukawa, T. A., Katherine Shear, M., Barlow, D. H., Gorman, J. M., Woods, S. W., Money, R., Etschel, E., Engel, R. R., & Leucht, S. (2009) · Depression and Anxiety · doi:10.1002/da.20532 · Cited by 163
Pharmacotherapy for anxiety disorders in children and adolescents
Ipser, J. C., Stein, D. J., Hawkridge, S., & Hoppe, L. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005170.pub2 · Cited by 159
Self-citationBandelow, B., Allgulander, C., Baldwin, D. S., Costa, D. L. D. C., Denys, D., Dilbaz, N., Domschke, K., Eriksson, E., Fineberg, N. A., Hättenschwiler, J., et al. (2023) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2022.2086295 · Cited by 158
Self-citationPharmacotherapy of anxiety disorders: A critical review
Koen, N., & Stein, D. J. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/nkoen · Cited by 151
Self-citationBoulenger, J.-P., Loft, H., & Florea, I. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112441866 · Cited by 127
“Furthermore, comparing rates of relapse across studies is inherently difficult because of the differences in criteria used to define remission during the open-label phase and relapse during the double-blind phase of such studies (Bandelow et al., 2006).”
ResultNeuroplasticity in Depressed Individuals Compared with Healthy Controls
Player, M. J., Taylor, J. L., Weickert, C. S., Alonzo, A., Sachdev, P., Martin, D., Mitchell, P. B., & Loo, C. K. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.126 · Cited by 127
Leichsenring, F., Salzer, S., Beutel, M. E., Herpertz, S., Hiller, W., Hoyer, J., Huesing, J., Joraschky, P., Nolting, B., Poehlmann, K., et al. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13111514 · Cited by 121
Möller, H.-J. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802264606 · Cited by 107
“It has variously been suggested that the corresponding cut-off score on the MADRS scale should be 58 of 59 (Carmody et al. 2006), B10 (Hawley et al. 2002), 510 (Zimmerman et al. 2004d), 511 (Bandelow et al. 2006).”
BackgroundKetamine and other glutamate receptor modulators for depression in bipolar disorder in adults
McCloud, T. L., Caddy, C., Jochim, J., Rendell, J. M., Diamond, P. R., Shuttleworth, C., Brett, D., Amit, B. H., McShane, R., Hamadi, L., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011611.pub2 · Cited by 102
Dean, R. L., Hurducas, C., Hawton, K., Spyridi, S., Cowen, P. J., Hollingsworth, S., Marquardt, T., Barnes, A., Smith, R., McShane, R., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011612.pub3 · Cited by 95
The empirical redefinition of the psychometric criteria for remission in bipolar disorder
Berk, M., Ng, F., Wang, W. V., Calabrese, J. R., Mitchell, P. B., Malhi, G. S., & Tohen, M. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.06.011 · Cited by 85
Stefanovics, E. A., Rosenheck, R. A., Jones, K. M., Huang, G., & Krystal, J. H. (2018) · Psychiatric Quarterly · doi:10.1007/s11126-017-9522-y · Cited by 74
Investigating Habituation to Premonitory Urges in Behavior Therapy for Tic Disorders
Houghton, D. C., Capriotti, M. R., Scahill, L. D., Wilhelm, S., Peterson, A. L., Walkup, J. T., Piacentini, J., & Woods, D. W. (2017) · Behavior Therapy · doi:10.1016/j.beth.2017.08.004 · Cited by 67
“Validity coefficients are also high for the CGI-I across many different psychiatric conditions in both pharmacological and psychosocial treatment paradigms (Bandelow, Baldwin, Dolberg, Andersen, & Stein, 2006; Leon et al., 1993; Leucht & Engel, 2006; Spielmans & McFall, 2006; Zaider et al., 2003).”
Backgroundvan der Lem, R., van der Wee, N. J. A., van Veen, T., & Zitman, F. G. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000330890 · Cited by 63
Internet-Delivered Cognitive Therapy for Social Anxiety Disorder: A Development Pilot Series
Stott, R., Wild, J., Grey, N., Liness, S., Warnock-Parkes, E., Commins, S., Readings, J., Bremner, G., Woodward, E., Ehlers, A., et al. (2013) · Behavioural and Cognitive Psychotherapy · doi:10.1017/s1352465813000404 · Cited by 61
Stein, D. J., Craske, M. G., Rothbaum, B. O., Chamberlain, S. R., Fineberg, N. A., Choi, K. W., de Jonge, P., Baldwin, D. S., & Maj, M. (2021) · World Psychiatry · doi:10.1002/wps.20919 · Cited by 60
Self-citationBuhrman, M., Fredriksson, A., Edström, G., Shafiei, D., Tärnqvist, C., Ljótsson, B., Hursti, T., Gordh, T., & Andersson, G. (2013) · European Journal of Pain · doi:10.1002/j.1532-2149.2012.00244.x · Cited by 60
Potvin, S., Charbonneau, G., Juster, R.-P., Purdon, S., & Tourjman, S. V. (2016) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2016.06.004 · Cited by 56
von Glischinski, M., Willutzki, U., Stangier, U., Hiller, W., Hoyer, J., Leibing, E., Leichsenring, F., & Hirschfeld, G. (2018) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.2179 · Cited by 54
White, K. S., Payne, L. A., Gorman, J. M., Shear, M. K., Woods, S. W., Saksa, J. R., & Barlow, D. H. (2013) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0030666 · Cited by 42
Chen, J., Nakano, Y., Ietzugu, T., Ogawa, S., Funayama, T., Watanabe, N., Noda, Y., & Furukawa, T. A. (2007) · BMC Psychiatry · doi:10.1186/1471-244x-7-69 · Cited by 42
Correa, K. A., Liu, H., & Shankman, S. A. (2019) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2019.01.001 · Cited by 37
Management of Treatment-Resistant Panic Disorder
Perna, G., & Caldirola, D. (2017) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-017-0128-7 · Cited by 36
Pollack, M. H., Endicott, J., Liebowitz, M., Russell, J., Detke, M., Spann, M., Ball, S., & Swindle, R. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.11.006 · Cited by 35
“A recent analysis indicated that when using CGI-I ratings as the external criterion, a HAMA reduction of 42% could be defined as a treatment response, in contrast to the typical definition of a P50% reduction (Bandelow et al., 2006).”
MethodA randomized controlled pilot trial of vilazodone for adult separation anxiety disorder
Schneier, F. R., Moskow, D. M., Choo, T.-H., Galfalvy, H., Campeas, R., & Sanchez-Lacay, A. (2017) · Depression and Anxiety · doi:10.1002/da.22693 · Cited by 35
Klumpp, H., Roberts, J., Kennedy, A. E., Shankman, S. A., Langenecker, S. A., Gross, J. J., & Phan, K. L. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.01.010 · Cited by 34
Thew, G. R., Kwok, A. P. L., Lissillour Chan, M. H., Powell, C. L. Y. M., Wild, J., Leung, P. W. L., & Clark, D. M. (2022) · Internet Interventions · doi:10.1016/j.invent.2022.100539 · Cited by 28
“Response was defined as an improvement on the LSAS between pretreatment and posttreatment greater than 31% (Bandelow et al., 2006).”
MethodThew, G. R., Powell, C. L., Kwok, A. P., Lissillour Chan, M. H., Wild, J., Warnock-Parkes, E., Leung, P. W., & Clark, D. M. (2019) · JMIR Formative Research · doi:10.2196/13446 · Cited by 24
“Response to treatment was defined as an improvement greater than 31% on the LSAS between pretreatment and posttreatment [43].”
MethodEMDR therapy for misophonia: A pilot study of case series
Jager, I., Vulink, N., de Roos, C., & Denys, D. (2021) · European Journal of Psychotraumatology · doi:10.1080/20008198.2021.1968613 · Cited by 18
Anxiety Symptom Severity and Functional Recovery Or Relapse
Stein, D. J., Bandelow, B., Dolberg, O. T., Andersen, H. F., & Baldwin, D. S. (2009) · Annals of Clinical Psychiatry · doi:10.1177/104012370902100204 · Cited by 14
Self-citationPayne, L. A., White, K. S., Gallagher, M. W., Woods, S. W., Shear, M. K., Gorman, J. M., Farchione, T. J., & Barlow, D. H. (2016) · Depression and Anxiety · doi:10.1002/da.22457 · Cited by 13
“The Clinical Global Improvement scale has good test-retest reliability among individuals with anxiety disorders and good interrater reliability.[25,26]”
Yoshinaga, N., Thew, G. R., Hayashi, Y., Matsuoka, J., Tanoue, H., Takanashi, R., Araki, M., Kanai, Y., Smith, A., Grant, S. H. L., et al. (2023) · JMIR Formative Research · doi:10.2196/45136 · Cited by 6
Metadata
- Authors
- Bandelow, B., Baldwin, D. S., Dolberg, O. T., Andersen, H. F., & Stein, D. J.
- Affiliations
- University of Göttingen (DE)
- University of Southampton (GB)
- Lundbeck (Denmark) (DK)
- University of Cape Town (ZA)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2006-09-15
- Volume
- 67
- Issue
- 09
- Pages
- 1428-1434
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1976277684
- Cited by
- 203
- References
- 0
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 7 · 2023: 4 · 2022: 5 · 2021: 10 · 2020: 1 · 2019: 17 · 2018: 14 · 2017: 19 · 2016: 14 · 2015: 9 · 2014: 10 · 2013: 16 · 2012: 11
- FWCI
- 15.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- symptom response, major depressive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, escitalopram, Clinical Global Impression Scale, standardized effect size, antidepressant response
- MeSH terms
- Anxiety Disorders, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Humans, Phobic Disorders, Placebos, Psychiatric Status Rating Scales, Psychometrics, Quality of Life, Research Design, Severity of Illness Index, Citalopram, Randomized Controlled Trials as Topic, Panic Disorder, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Disease-Free Survival, Diagnostic and Statistical Manual of Mental Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.